Hohnhaus & Jansenberger and Cathay Capital lead consortium buyout of medifa

medifa healthcare group (medifa), an owner-run one-stop-shop provider of medical technology for operating rooms, has been acquired by a consortium led by Hohnhaus & Jansenberger and Cathay Capital Private Equity through its Small Cap strategy. 

The transaction includes a full recapitalisation of the Company’s balance sheet.  

Christian Keller, CEO of medifa, rolled his stake in the Company and remains a significant shareholder. He says: “Thanks to the commitment of both existing and new investors, medifa now benefits from a shareholder base that is wholly dedicated to continuing and accelerating the successful growth path initiated by the Company since 2015. medifa faced the pandemic with flying colours and has begun the construction of its new central production site of more than 30,000 square meters in Baden-Baden, with the aim of consolidating its manufacturing capabilities to further improve its production efficiency. Furthermore, medifa is continuing the roll-out of its new innovative products, such as the medifa H!light and 8000 hybrid OR table.” 

Partnering with Yielco as co-investor, Hohnhaus & Jansenberger is an operationally driven mid-market investment firm based in Munich. Dr Wolfgang Hohnhaus, Managing Partner at Hohnhaus & Jansenberger Gruppe and co-CEO at medifa, adds: “We are pleased to remain as a significant shareholder in medifa and to continue to support its growth trajectory. We are confident in the ongoing added-value generated by our longstanding and trust-based partnership with medifa and Cathay Capital, and we are delighted to welcome onboard Yielco as a new co-investor and partner. We look forward to exciting new developments ahead.” 

With Cathay Capital’s global resources, deeply rooted local business development know-how, and thorough knowledge of the healthcare sector, medifa has found the ideal partner to accelerate its growth in foreign markets. Thanks to Cathay Capital’s support, medifa has established a strategic partnership in China with a leading provider of medical gas and air purification systems for operating rooms. This partnership notably provides medifa with assistance in obtaining regulatory approvals in China for all relevant products, setting-up showrooms, and providing a network for local distribution and installation, as well as additional customer services on the ground. 

Mingpo Cai, Founder, Chairman and CEO of Cathay Capital, concludes: “We are glad to renew our support to medifa following our initial investment in 2019. Cathay Capital will continue to add to the growth momentum of this promising medical technology group on its journey of global expansion. This reinvestment further proves our strong conviction in medifa’s long-term growth potential driven by the Company’s deeply integrated value chain, globally recognised brand and proven innovation capabilities.”